Anderson Woodrow D 4

What Happened

• Woodrow D. Anderson, Indivior Pharmaceuticals' Chief Accounting Officer, was granted a total of 30,878 restricted stock units (RSUs): 6,903 RSUs on Feb 10, 2026 and 23,975 RSUs (a performance-based award) on Feb 9, 2026. Both grants show $0 per share at issuance (typical for RSU compensation), so no cash was paid by the insider.
• The 6,903 RSUs vest in three equal annual installments beginning Feb 10, 2027, subject to continued service. The 23,975 performance RSUs were originally granted Mar 3, 2023, certified for performance on Feb 9, 2026, and vest (subject to continued employment) on Mar 3, 2026.

Key Details

• Transaction dates/prices: Feb 9, 2026 — 23,975 RSUs @ $0.00 (performance award certified); Feb 10, 2026 — 6,903 RSUs @ $0.00.
• Total shares awarded: 30,878 RSUs.
• Shares owned after transaction: not specified in the Form 4 summary provided.
• Vesting notes: 6,903 RSUs vest in three equal annual installments starting Feb 10, 2027; 23,975 performance RSUs vest Mar 3, 2026 if employment continues.
• Filing: Form 4 filed Feb 12, 2026 reporting events dated Feb 9–10, 2026; no indication in the filing that this was late.
• Exhibit: Power of Attorney filed (Exhibit 24).

Context

• RSUs are compensation awards giving the recipient the right to receive shares in the future if vesting conditions are met; a $0 grant price is standard for such awards and does not mean market value is zero — it means the insider paid nothing to receive the award.
• The 23,975-share item was a performance-based award whose performance conditions were certified on Feb 9, 2026; vesting still requires continued employment through the vest date.
• These awards reflect company compensation practices rather than open-market buying or selling; they do not by themselves indicate the insider’s personal trading view.